A new method for prompting cells to create specific proteins can more accurately focus on which cells make the proteins and when. Given the diverse purposes of proteins in the body, this could lead to advances in medical treatments and research, among … […]
Gilead Sciences said its cancer drug Trodelvy prolonged the survival of women with the most common form of breast cancer by just under 30%. […]
What can worms teach us about immortality? How does one become the Godfather? And where does Biogen go from here? Find out on the new episode of “The Readout LOUD”… […]
Sequencing behemoth Illumina won its case against the FTC in its bid to hold onto Grail, a Bay Area early cancer detection company. […]
Third Rock Venture partners Abbie Celniker and Reid Huber spoke with STAT about their plans for investing their sixth and largest fund. The lion’s share of the $1.1 billion they… […]
The cancer drug Trodelvy reduced the risk of tumors progressing by 34% compared to chemotherapy in patients with the most common form of metastatic breast cancer. […]
During the worst moments at Theranos, Tyler Shultz ran. To burn off the stress, he logged 20 miles at a clip in the mountains. And when that didn’t work, he… […]
Bay Area biotech Ultima Genomics on Tuesday claimed that its technology can sequence a whole human genome for $100, making it a surprise player in the race to read DNA… […]
Two months after being sued by Illumina over the alleged theft of trade secrets, Bay Area biotech Guardant Health fired back this week, rejecting the DNA sequencing giant’s claims and… […]
Helmy Eltoukhy and AmirAli Talasaz, Guardant’s co-CEOs, discussed the company’s upcoming milestones, how they plan to separate themselves from the competition, and the future of liquid biopsies. […]
Copyright © 2022 Biotech Networks, LLC
